Navigation Links
Sepsis and Septic Shock on the Rise, Affecting Younger Patients

DURHAM, N.C., Jan. 11 /PRNewswire/ -- bioMerieux, a world leader in the field of in vitro diagnostics, today released its results of a comprehensive survey of emergency department and critical care physicians. The vast majority of these doctors reported that sepsis and septic shock--the result of serious infections--is on the rise in U.S. hospitals, affecting increasingly younger patients. The surveyed doctors attributed the increase to the overuse of antibiotics, which is rendering these once wonder-drugs ineffective.

Sepsis, a usually fatal medical condition caused by the body's response to a severe infection of the blood and/or tissues, affects 5-10 percent of all hospital patients, leading to an increase of about $5 billion in U.S. health-care costs annually.(1) Nearly 300 emergency and critical care doctors were surveyed at two major medical conferences - the American College of Emergency Physicians Annual Conference, held in Boston in October 2009, and the American College of Chest Physicians Annual Meeting, held in San Diego in November 2009.

When asked if they have seen an increasing rate in sepsis in their hospitals during the last decade, the answer was unequivocally "yes." Seventy-six percent of the physicians surveyed said the incidence of sepsis is on the rise. In addition, nearly 60 percent said sepsis is affecting more patients than it did 10 years ago.

Sixty-three percent of doctors surveyed indicated that the No. 1 reason for younger patients becoming septic was an increase in multi-drug-resistant microorganisms, which is caused by the widespread overuse of antibiotics. In a recent study published by Roberts et al, examining the hospital and societal costs of antibiotic-resistant infections (ARIs) at a Chicago hospital, patients who suffered from these infections remained in the hospital between 6.4-12.7 days longer than those who were not infected and had a significantly increased risk of death - two-fold higher than in patients without ARIs, with an attributable mortality rate of 6.5 percent.(2)

"Sepsis is often a life-threatening condition, compounded by multidrug-resistant organisms and patients who live longer with serious underlying co-morbidities," said Mark H. Oltermann, M.D., director of the Medical ICU at John Peter Smith Hospital in Fort Worth, Texas.

When asked if biomarkers, or telltale biochemical indicators of infection, are used to help diagnose severe infections that could lead to sepsis, the vast majority (nearly 70 percent) of the 281 surveyed doctors said yes. However, only 6 percent of these doctors reported using procalcitonin (PCT) as a biomarker to help them manage suspected sepsis patients. When asked to qualify the improvement that PCT testing could bring to emergency and critical care patients, 51 percent said the test would dramatically improve the quality of care that patients with suspected sepsis would receive in U.S. hospitals.

"Sepsis is a disease that when diagnosed early and treated effectively, more lives can be saved than almost any other disease," Dr. Oltermann added. "It is critical that we add state-of-the art tools to our arsenal to help battle sepsis. PCT is one of those tools."

To review the complete results of the 2009 Sepsis Survey Report, which covers additional aspects of sepsis diagnosis and care, infectious diseases biomarkers, and how ED and CC physicians rank in importance the timely issues of health-care reform, liability reform, and the emergence of multidrug-resistant organisms, please visit

About Procalcitonin (PCT)

PCT is the prohormone of calcitonin and is not normally present in the bloodstream of a healthy individual. PCT is released from multiple organs when there is a systemic bacterial infection. The blood plasma level of PCT is a reflection of the severity of bacterial infection, ranging from slightly elevated concentrations in infections with minor systemic inflammatory response to very high values in cases of severe sepsis and septic shock. Since the first report in 1993 on the association of serum PCT levels with bacterial infection,(3) there is a solid body of evidence in the literature on its utility for early diagnosis and prognosis, monitoring the clinical course as well as its utility to guide therapy.(4)


  1. Balk, R. Severe Sepsis and Septic Shock: Definitions, Epidemiology, And Clinical Manifestations; Critical Care Clinics, Volume 16, Issue 2, Pages 179-192.
  2. Roberts RR, Hota B, Ahmad I, Scott RD II, Foster SD, Abbasi F, Schabowski S, Kampe LM, Ciavarella GG, Supino M, Naples J, Cordell R, Levy SB, Weistein RA. Hospital and Societal Costs of Antimicrobial-Resistant Infections in a Chicago Teaching Hospital: Implications for Antibiotic Stewardship. Clin Infect Dis 2009:49 (15 October):1175-84.
  3. Assicot M, Gendrel D, Garsin H, et al. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993; 341: 515-518.
  4. Christ-Crain M, Muller B. Procalcitonin in bacterial infections - hype, hope or more or less? Swiss Med Wkly 2005; 135: 451-460.

About bioMerieux

Advancing diagnostics to improve public health

A world leader in the field of in vitro diagnostics for more than 45 years, bioMerieux is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2008, revenues reached 1.111 billion euros with 84% of sales outside of France. bioMerieux provides diagnostic solutions (reagents, instruments, software) that determine the source of disease and contamination to improve patient health and ensure consumer safety. Our products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. bioMerieux is listed on the NYSE Euronext Paris market (Symbol: BIM - ISIN: FR0010096479). Other information can be found at

SOURCE bioMerieux



SOURCE bioMerieux
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First High-Res 3-D Structures of Mammalian HSP90 Protein Solved, Key to Better Targets for AIDS, Sepsis, Cancer Drugs
2. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
3. Results From Phase II Trial in Critical Care Medicine Showed Eritoran Tetrasodium (E5564) To Be Well Tolerated in Patients with Severe Sepsis
4. Medizone International, Inc. (MZEI.PK): Trials of the AsepticSure Hospital Sterilization System Have Begun
5. Hand Washing with 4% CHG Antiseptic Kills Flu Viruses
6. Medizone International Announces Third Round of AsepticSure
7. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
8. Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
9. With 2009 H1N1 Cases on the Rise, New CDC-Recommended Vaccine Helps Protect Families Against Illness
10. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
11. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
Post Your Comments:
(Date:11/27/2015)... 27, 2015 --> ... go online. The potential to save costs, improve treatment ... far from fully exploited as yet. Here, particular emphasis ... either via mobile tablet or directly at the patients, ... ) -->      (Photo: ...
(Date:11/26/2015)... India , November 27, ... --> --> ... personal emergency response system (PERS) ... steadily for 5 years with ... region expected to see a ...
(Date:11/26/2015)... November 26, 2015 --> ... use SyMRI to find optimal contrast weighting of MRI ... and has signed a research agreement with SyntheticMR in order ... Using SyMRI, it is possible to generate multiple contrast images ... the patient has left, thus making it possible to both ...
Breaking Medicine Technology:
(Date:11/29/2015)... San Jose, CA (PRWEB) , ... November 29, 2015 , ... ... Bay Area, is proud to announce their December, 2015, featured apartment community: Epic. In ... looking for corporate housing in the tight Bay Area rental market to efficiently find ...
(Date:11/28/2015)... , ... November 28, 2015 , ... Trying to relax ... created the COUCH BUDDY. "I conceived of this design due to personal experience with ... couch users. It promotes relaxation and convenience, as well as increases support. It also ...
(Date:11/27/2015)... , ... November 28, 2015 , ... There is only ... outperform our billings from last year? , This question has not been an easy ... coming to the retirement age and the younger workforce don’t share the same discipline ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... way that they are handling security in light of the recent terrorist attacks in ... an attempt to stop an attack from reaching U.S. soil. Especially around special events ...
(Date:11/27/2015)... ... November 27, 2015 , ... An inventor, from ... dispense prescription medications at home, so he invented the patent-pending ELECTRONIC M.D. , ... prescription medications. In doing so, it could help to prevent potential overdose situations. ...
Breaking Medicine News(10 mins):